FDA warns of increased risk of death from febuxostat I n February, FDA issued a new boxed warning-its most prominent warning-for the gout medication febuxostat (Uloric-Takeda), stating that patients who take the drug could be at an increased risk of death, especially death from heart-related issues. Health professionals can also expect a new Medication Guide for patients taking febuxostat.
The new boxed warning is largely attributed to the CARES (Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities) study, a randomized postmarket clinical trial that included more than 6,000 patients with gout who were treated with either febuxostat or allopurinol.
For patients treated with febuxostat, 15 deaths from heart-related causes were observed for every 1,000 patients treated for a year, compared with 11 heart-related deaths per 1,000 patients who took allopurinol for a year. Results turned up 26 deaths from any cause per 1,000 patients on febuxostat for a year versus 22 deaths for those treated with allopurinol.
"It is important to note that in the CARES study, most patients taking xanthine-oxidase inhibitors were on allopurinol versus febuxostat," said Maha Saad, PharmD, BCGP, BCPS, associate clinical professor at St. John's University College of Pharmacy and Health Sciences in Queens, NY. "This could be attributed to the long-term experience with allopurinol and the higher cost with febuxostat."
Allopurinol vs. febuxostat
In general, more patients with gout take allopurinol because it's less expensive than febuxostat. In addition, European guidelines favor allopurinol over febuxostat, although American guidelines don't give a preference for a particular xanthine-oxidase inhibitor.
The trial had a large discontinuation rate as well: 57.3% in the febuxostat arm discontinued, versus 55.9% in the allopurinol arm. NSAID use and the absence of low-dose aspirin were identified as interactions for cardiovascular death, favoring allopurinol. "It's hard to decipher which patients may be affected by the boxed warning," said Saad, who is also a member of the board of directors for the Gout & Uric Acid Education Society. "Patients with underlying cardiovascular diseases taking an NSAID and not taking baby aspirin might be at increased risk. A Risk Evaluation and Mitigation Strategy (REMS) program might limit the use of the drug and ensure its use under certain circumstances."
Because febuxostat is a more potent inhibitor of xanthine oxidase than allopurinol, Saad said, it may have a greater effect on the xanthine oxidasedependent reduction of nitric oxidase as well as a greater ability to lower urate levels, resulting in more harm on overall cardiovascular health compared with allopurinol.
Hyperuricemia and gout have also been associated as risk factors for cardiovascular disease, including death from heart-related issues. Treatment with urate-lowering therapy lowers this risk.
When allopurinol isn't the best option "I don't see febuxostat a ton in practice," said Cortney Mospan, PharmD, BCACP, BCGP, assistant professor of pharmacy at Wingate University School of Pharmacy in North Carolina. "Maybe one febuxostat for every 10 allopurinol."
Mospan said she expects the boxed warning to affect few patients. However, in patients for whom allopurinol isn't the best option-especially those with chronic kidney disease-it could have major implications and confound prescribers as they decide what to do next. "There's a significant misconception that allopurinol should be avoided or renally dose-adjusted to reduce the risk of allopurinol hypersensivity syndrome (AHS)," said Mospan. But data do not support that higher doses of allopurinol increase AHS risk; rather, the intensity of the starting dose is a greater predictor.
"Most chronic kidney disease patients on allopurinol do not achieve their uric acid goal, so those are the patients I think this will have an impact on, and clinicians may struggle with what to do," Mospan said.
Patient education
The prevalence of gout in the U.S. population has been rising steadily over the past few decades, with approximately 8.3 million Americans having gout, according to the latest statistics.
"As pharmacists, we should be checking for side effects and helping to adjust therapy, making sure our patients are reaching their uric acid goals just like we would with blood pressure or A1C."
Gout is perceived to be a minor disease because of asymptomatic hyperuricemia and the infrequency of acute attacks. But evidence is building that it has risks equivalent to heart attacks for patients with diabetes.
Hypertension, obesity, metabolic syndrome, type 2 diabetes, and chronic kidney disease promote hyperuricemia. Other contributors are certain purine-rich meats, high-fructose corn syrup, alcohol consumption, sedentary behavior, and widespread prescribing of thiazide and loop diuretics for cardiovascular disease.
When patients are treated with urate-lowering therapy, adherence is typically low, and many patients are not treated to their target uric acid goal, said Mospan.
"As pharmacists, we should be checking for side effects and helping to adjust therapy, making sure our patients are reaching their uric acid goals just like we would with blood pressure or A1C. [We should] identify causes of uric acid elevation and try to remove these when possible."
Saad said that most health care providers believe that it's challenging for patients with gout to adhere to dietary recommendations.
"A large emphasis on the role of dietary factors in gout and limiting high purine intake are also important counseling points," Saad said. "Providing patients with written educational materials in lay language and dietary guidelines may help."
In addition, she said, pharmacists can improve gout management through better patient education, such as promoting long-term medication adherence and awareness about recognizing gout flares and how to handle them appropriately.
The American College of Rheumatology expects to release a new updated guideline on gout in late 2019 or early 2020. "These updated guidelines will hopefully provide better options and recommendations for treating gout patients as well as reflect on this new data surrounding febuxostat," Saad said.
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Currently available gout treatments
Acute treatment NSAIDs
• Most common agent is indomethacin 50 mg three times/day.
• Monitor for GI bleed and kidney injury.
• A boxed warning indicates that NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk.
Colchicine
• Dose is 1.2 mg initially, then 0.6 mg 1 hour later, then 0.6 mg to 1.2 mg/day until the gout attack resolves.
• Avoid in patients with renal and/or hepatic insufficiency.
• Contraindicated in patients taking clarithromycin. Corticosteroids
• Routes of administration are oral, I.M., and intra-articular.
• Variable dosing; however, oral agents should be tapered off to avoid rebound flares.
Chronic treatment Allopurinol
• Dose is 100 mg once daily initially; can take up to 300 mg daily. Use with caution in patients with renal insufficiency.
• Conduct genetic testing before initiating therapy to prevent adverse skin reactions due to hypersensitivity. Febuxostat
• Dose is 40 mg once daily; may increase to 80 mg/day if serum uric acid > 6 mg/dL after 2 weeks of 40-mg dose.
• Contraindicated in patients receiving azathioprine or mercaptopurine.
• Reserve for use in patients who have failed or do not tolerate allopurinol. Probenecid
• Dose is 250 mg twice daily; can titrate up to 2 g/day.
• Increases risk for nephrolithiasis; encourage hydration and possible alkalization with potassium citrate. • Has multiple drug interactions (Tylenol, NSAIDs, antibiotics) . Colchicine
• Dose is 0.6 mg or 1.2 mg once daily.
• Increased risk for rhabdomyolysis with concurrent use or statins of clarithromycin. Pegloticase
• Dose is 8 mg intravenously every 2 weeks.
• Indicated only for refractory gout.
• Has warning for use in patients with heart failure.
• Hypersensitivity and anaphylactoid reactions have been reported during and after administration.
• Expensive (>$5,000 per dose). Lesinurad
• Decrease in renal reabsorption of uric acid; however, drug has known renal and cardiovascular complications, particularly with a 400-mg dose.
• Inwood announced it is discontinuing U.S. marketing of lesinurad (both Zurampic and Duzallo) effective February 1, 2019. The company stated that this is a business decision not related to the agent's efficacy and safety. Inwood recommends that patients who are currently on either Zurampic or Duzallo contact their health care provider to discuss alternative treatment options.
